Related Experiment Video
Updated: Aug 12, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Repaglinide: prandial glucose regulation in clinical practice
1Diabetes Research Unit, Llandough Hospital, Penarth, South Glamorgan, UK. owensdr@cf.ac.uk
Diabetes, Obesity & Metabolism
|February 28, 2001
Summary
Repaglinide, a prandial glucose regulator, effectively manages type 2 diabetes by targeting postmeal glucose spikes. It improves overall glycemic control and quality of life without increasing hypoglycemia risk.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Diabetes Management
Background:
- Type 2 diabetes management focuses on long-term glycemic control.
- Postprandial hyperglycemia contributes to diabetic complications.
- Prandial glucose regulation targets postmeal glucose excursions.
Purpose of the Study:
- To introduce repaglinide as the first prandial glucose regulator.
- To evaluate repaglinide's efficacy in managing postprandial hyperglycemia.
- To assess repaglinide's impact on overall glycemic control and quality of life.
Main Methods:
- Clinical studies comparing repaglinide with glibenclamide.
- Assessment of repaglinide's insulinotropic action and duration.
- Evaluation of repaglinide in monotherapy and combination therapy.
Main Results:
- Repaglinide effectively reduces postprandial glucose excursions without increasing hypoglycemia risk.
- Repaglinide demonstrates superiority over glibenclamide in short-term postprandial control.
- Longer-term studies show repaglinide provides glycemic control equivalent to sulfonylureas.
- Repaglinide improves quality of life due to flexible meal patterns.
- Repaglinide is effective as a first-line agent and in combination therapy.
Conclusions:
- Repaglinide is a novel prandial glucose regulator for type 2 diabetes.
- It offers effective postprandial glucose control and improves quality of life.
- Repaglinide is a valuable option for monotherapy and combination therapy in type 2 diabetes management.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...